Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2640 • ACR Convergence 2025
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Sho Fukui¹, Hilde Ørbo², Sara Tedeschi¹, Hongshu Guan³, Leslie Harrold⁴, Heather Litman⁵ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Diakonhjemmet Hospital, Oslo, Norway, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴CorEvitas, Northborough, MA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Kidney dysfunction is common in patients with rheumatoid arthritis (RA). However, there has been limited and conflicting evidence on the effectiveness of biologic and…
Abstract Number: 2266 • ACR Convergence 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Mohammad Movahedi¹, Angela Cesta¹, Sibel Aydin², Pooneh Akhavan³, Tetyana Kendzerska⁴, Claire Bombardier¹ and Bindee Kuriya⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³self-employed, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Mississuaga, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Observational studies on RA therapeutic classes have shown conflicting results on their impact on mortality and cancer. When analyzing long-term outcomes, it is essential…
Abstract Number: 1541 • ACR Convergence 2025
Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Qizhi Yuan¹, Qinli Qin², Leyao Ma¹ and Mengtao Li³, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Dongguan Kanghua Hospital, Dongguan, Guangdong, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvements and recurrent relapses. The objectives of treatment include ensuring long-term patient survival, preventing…
Abstract Number: 1347 • ACR Convergence 2025
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Aakanksha Pitliya¹, Srivatsa Surya Vasudevan², Sarthak Sharma³, Bijay Mukesh Jeswani⁴, Tanya Ratnani⁵ and Rajesh Thirumaran⁶, ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Louisiana State University Health Sciences Center, Shreveport, LA, ³Government Medical College, Jammu, Jammu, Jammu and Kashmir, India, ⁴GCS Medical College, Hospital and Research Center, Ahmedabad, Gujarat, India, ⁵Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh, India, ⁶Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are commonly used disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). While both are widely prescribed,…
Abstract Number: 1042 • ACR Convergence 2025
Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Eric Roberts¹, gabriela Schmajuk², Diana Ung³, Mackenzie Clark³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA
Background/Purpose: In 2023 patent exclusivity for adalimumab expired and nine biosimilars were introduced to the U.S. market with a tenth launched in May 2024. The…
Abstract Number: 0871 • ACR Convergence 2025
The gut microbiome shapes MTX pharmacology and is linked to treatment outcomes
Vanya Sofia Villa Soto¹, Diego Orellana², Erin Reilly³, Chloe Heath², Alexandra Degraeve², Mohana Mukherjee², darren Dumlao², Rebecca Blank⁴, steven Yu², Noah Perlmutter², Judith Ashouri², Jose Scher⁵, andrew Patterson³, Peter Turnbaugh² and Renuka Nayak⁶, ¹University of California, San Francisco, San Francics, CA, ²University of California, San Francisco, San Francisco, CA, ³Pennsylvania State University, University Park, PA, ⁴NYU Langone Health, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Despite advances in targeted therapeutics, methotrexate (MTX) remains the first-line therapy in the treatment of rheumatoid arthritis (RA) and other inflammatory arthritides. However, more…
Abstract Number: 0481 • ACR Convergence 2025
Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Chandrashekara MN¹, AASTHA KHULLAR², Bidyalaxmi Leishangthem³, Shankar Naidu⁴, Varun Dhir⁵ and Sanjay Jain⁴, ¹PGIMER, Chandigarh, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, CHANDIGARH, Chandigarh, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴Post graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, Chandigarh, India, ⁵PGIMER, CHD, INDIA, CHANDIGARH, Chandigarh, India
Background/Purpose: Methotrexate (MTX) polyglutamates (MTX-PGs), the intracellular active forms of MTX, are hypothesized to reflect cumulative exposure and potentially predict therapeutic efficacy in rheumatoid arthritis…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 2571 • ACR Convergence 2025
Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Griffin Reed¹, Jeffrey Yang¹, Georges El Hasbani¹, Cynthia Crowson², Hannah Langenfeld¹, Jeffrey Sparks³, Bryant England⁴, gabriela Schmajuk⁵, Kaleb Michaud⁴, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Methotrexate laboratory monitoring is highly resource intensive, and recent evidence questions whether the true toxicity of methotrexate has been over-estimated. Therefore, we aimed to…
Abstract Number: 2228 • ACR Convergence 2025
COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis
Chase Verdugo¹, Yazin Hindosh¹, Akram Hindosh¹, Jonathan Sayegh¹, Bassam Mitri¹, Johnny Youssef¹, Tyler On¹, Faissal Stipho² and Issa Batarseh², ¹University of Arizona College of Medicine Tucson, Tucson, AZ, ²Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by immune system dysregulation, and it is commonly treated with either conventional or biologic Disease-Modifying Antirheumatic…
Abstract Number: 1477 • ACR Convergence 2025
Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Beste Acar¹, Berkay Aktas¹, Oguzhan Omer Kizilkaya¹, Zekayi Kutlubay² and serdal Ugurlu³, ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Dermatology, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: This study evaluates the contributions of large language models (LLMs) in clinical decision-making for atypical presentations of systemic lupus erythematosus (SLE). It focuses on…
Abstract Number: 1322 • ACR Convergence 2025
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
Sara Salas Santamaría¹, Marta Chao Moreira², Manuel Juárez³, Marta Novella-Navarro², Pilar Nozal², Ana Martínez², Carolina Tornero⁴, Cristina Bohorquez⁵, Ana Sánchez², Carmen Cámara², Eduardo López², Eugenio de Miguel² and Chamaida Plasencia-Rodríguez², ¹Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵La Paz University Hospital, Alcalá De Henares, Spain
Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
Abstract Number: 1040 • ACR Convergence 2025
Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
Cristina Hurley¹, Megha Kotha², Jisna Paul³ and Jeff Barbee⁴, ¹Carilion Clinic, Roanoke, VA, ²Ohio State University, Columbus, OH, ³Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, ⁴Ohio State University Wexner Medical Center, Columbus
Background/Purpose: This study assesses the impact of a clinical pharmacist-directed intervention on medication adherence and clinical outcomes in patients with rheumatoid arthritis, psoriatic arthritis, and…
Abstract Number: 0795 • ACR Convergence 2025
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
Ismael Sanchez-Pareja¹, Daniel Toro², Carlos Pérez Sánchez³, Laura muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño⁴, Sagrario Corrales¹, Lydia Formanti Alonso⁵, Rafaela Ortega-Castro⁶, Jerusalén Calvo⁵, Lourdes Ladehesa⁷, Concepción Aranda-Valera⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero Contreras⁵ and Chary López pedrera¹⁰, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…

1
2
3
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].